340B “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicts.

340B Won’t be Overlooked if There’s a Grand Bargain on Drug Pricing, Analyst Predicts

The 340B program “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicted this week during a talk on drug pricing reform at the 340B Coalition virtual summer conference.

“I do want to stress, manufacturers are talking about some kind of grand bargain on drug pricing,” said McCaughan, a contributor to and the former editor-in-chief of The Pink Sheet, a leading drug industry trade publication. “They will not be overlooking the 340B program. None of you will be overlooking the 340B program either. It’s going to be an important part of the conversation.”

The 340B program “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicted this week during a talk on drug pricing reform at the 340B Coalition virtual summer conference.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer